APPROVED_FOR_MARKETINGNot Applicable

3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)

United States

Plain-language summary

The purpose of this study is to determine the effectiveness and adverse effects of 3,4-diaminopyridine for the treatment of the Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenic Syndromes (CMS).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * LEMS diagnosis OR Pre or Post Synaptic CMS diagnosis * 18 years or older * Females must have negative pregnancy test and be willing to practice an effective form of birth control * No prolonged QT syndrome as indicated by baseline EKG Exclusion Criteria: * Known sensitivity to 3,4-DIAMINOPYRIDINE * History of seizures and/or severe asthma

Trial details

NCT IDNCT00872950

SponsorLahey Clinic

Sponsor typeOTHER

Study typeEXPANDED_ACCESS

View on ClinicalTrials.gov More Lambert-Eaton Myasthenic Syndrome trials